Works by Grünwald, Viktor

Results: 112
    1

    On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC.

    Published in:
    Oncology & Therapy, 2025, v. 13, n. 2, p. 275, doi. 10.1007/s40487-025-00334-6
    By:
    • Szabados, Bernadett E.;
    • Guerrero-Ramos, Félix;
    • Grande, Enrique;
    • Grivas, Petros;
    • Grünwald, Viktor;
    • Miguel, Marta Carpintero;
    • Hussain, Syed A.;
    • Kulkarni, Girish S.;
    • Wilson, Ana Lisa;
    • Shore, Neal D.;
    • Sridhar, Srikala S.;
    • Hoyt, Mary;
    • Strumeier, Samantha;
    • Sutton, Jennifer;
    • Brinkmann, Julia;
    • Teresi, Rosemary E.;
    • Todenhöfer, Tilman
    Publication type:
    Article
    2
    3
    4
    5

    Final Analysis of a Noninterventional Study on Cabozantinib in Patients With Advanced Renal Cell Carcinoma After Prior Checkpoint Inhibitor Therapy of the German Interdisciplinary Working Group on Renal Tumors (IAG-N).

    Published in:
    Clinical Genitourinary Cancer, 2024, v. 22, n. 5, p. N.PAG, doi. 10.1016/j.clgc.2024.102159
    By:
    • Viktor, Grünwald;
    • Martin, Bögemann;
    • Mohammad-Reza, Rafiyan;
    • Günter, Niegisch;
    • Marco, Schnabel;
    • Anne, Flörcken;
    • Michael, Maasberg;
    • Christoph, Maintz;
    • Mark-Oliver, Zahn;
    • Anke, Wortmann;
    • Andreas, Hinkel;
    • Jochen, Casper;
    • C, Darr;
    • Thomas, Hilser;
    • M, Schulze;
    • Disorn, Sookthai;
    • Philipp, Ivanyi
    Publication type:
    Article
    6
    7
    8

    Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.

    Published in:
    Targeted Oncology, 2023, v. 18, n. 5, p. 639, doi. 10.1007/s11523-023-00987-1
    By:
    • Motzer, Robert J.;
    • Russo, Paul;
    • Grünwald, Viktor;
    • Tomita, Yoshihiko;
    • Zurawski, Bogdan;
    • Parikh, Omi;
    • Buti, Sebastiano;
    • Barthélémy, Philippe;
    • Goh, Jeffrey C.;
    • Ye, Dingwei;
    • Lingua, Alejo;
    • Lattouf, Jean-Baptiste;
    • Albigès, Laurence;
    • George, Saby;
    • Shuch, Brian;
    • Sosman, Jeffrey;
    • Staehler, Michael;
    • Vázquez Estévez, Sergio;
    • Simsek, Burcin;
    • Spiridigliozzi, Julia
    Publication type:
    Article
    9
    10
    11

    Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data.

    Published in:
    Cancer Immunology, Immunotherapy, 2024, v. 73, n. 2, p. 1, doi. 10.1007/s00262-023-03621-1
    By:
    • Yanagisawa, Takafumi;
    • Mori, Keiichiro;
    • Matsukawa, Akihiro;
    • Kawada, Tatsushi;
    • Katayama, Satoshi;
    • Bekku, Kensuke;
    • Laukhtina, Ekaterina;
    • Rajwa, Pawel;
    • Quhal, Fahad;
    • Pradere, Benjamin;
    • Fukuokaya, Wataru;
    • Iwatani, Kosuke;
    • Murakami, Masaya;
    • Bensalah, Karim;
    • Grünwald, Viktor;
    • Schmidinger, Manuela;
    • Shariat, Shahrokh F.;
    • Kimura, Takahiro
    Publication type:
    Article
    12
    13
    14

    Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.

    Published in:
    Acta Oncologica, 2017, v. 56, n. 7, p. 1013, doi. 10.1080/0284186X.2017.1315173
    By:
    • Young, Robin J.;
    • Litière, Saskia;
    • Lia, Michela;
    • Hogendoorn, Pancras C. W.;
    • Fisher, Cyril;
    • Mechtersheimer, Gunhild;
    • Daugaard, Søren;
    • Sciot, Raf;
    • Collin, Françoise;
    • Messiou, Christina;
    • Grünwald, Viktor;
    • Gronchi, Alessandro;
    • van der Graaf, Winette;
    • Wardelmann, Eva;
    • Judson, Ian
    Publication type:
    Article
    15
    16
    17
    18
    19
    20
    21
    22

    Treatment Algorithm for Metastatic Renal Cell Carcinoma - Recommendations Based on Evidence and Clinical Practice.

    Published in:
    Oncology Research & Treatment, 2014, v. 37, n. 3, p. 136, doi. 10.1159/000360179
    By:
    • Bergmann, Lothar;
    • Beck, Jochaim;
    • Bothe, Kathrin;
    • Brinkmann, Olaf a.;
    • Buse, Stephan;
    • Goebell, Peter J.;
    • Grünwald, Viktor;
    • Holzapfel, Konstantin;
    • Kübler, Hubert;
    • Marschner, Norbert W.;
    • Mickisch, Gerald;
    • Schultze-Seemann, Wolfgang;
    • Siebels, Michael;
    • Siemer, Stephan;
    • Störkel, Stephan;
    • Gschwend, Jürgen E.
    Publication type:
    Article
    23
    24

    Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study.

    Published in:
    Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-44103-9
    By:
    • Váradi, Melinda;
    • Horváth, Orsolya;
    • Módos, Orsolya;
    • Fazekas, Tamás;
    • Grunewald, Camilla M.;
    • Niegisch, Günter;
    • Krafft, Ulrich;
    • Grünwald, Viktor;
    • Hadaschik, Boris;
    • Olah, Csilla;
    • Maráz, Anikó;
    • Furka, Andrea;
    • Szűcs, Miklós;
    • Nyirády, Péter;
    • Szarvas, Tibor
    Publication type:
    Article
    25

    Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study.

    Published in:
    Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-44103-9
    By:
    • Váradi, Melinda;
    • Horváth, Orsolya;
    • Módos, Orsolya;
    • Fazekas, Tamás;
    • Grunewald, Camilla M.;
    • Niegisch, Günter;
    • Krafft, Ulrich;
    • Grünwald, Viktor;
    • Hadaschik, Boris;
    • Olah, Csilla;
    • Maráz, Anikó;
    • Furka, Andrea;
    • Szűcs, Miklós;
    • Nyirády, Péter;
    • Szarvas, Tibor
    Publication type:
    Article
    26
    27

    Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.

    Published in:
    Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1343027
    By:
    • Grünwald, Viktor;
    • Powles, Thomas;
    • Masatoshi Eto;
    • Kopyltsov, Evgeny;
    • Sun Young Rha;
    • Porta, Camillo;
    • Motzer, Robert;
    • Hutson, Thomas E.;
    • Méndez-Vidal, María José;
    • Sung-Hoo Hong;
    • Winquist, Eric;
    • Goh, Jeffrey C.;
    • Maroto, Pablo;
    • Buchler, Tomas;
    • Takagi, Toshio;
    • Burgents, Joseph E.;
    • Perini, Rodolfo;
    • Cixin He;
    • Okpara, Chinyere E.;
    • McKenzie, Jodi
    Publication type:
    Article
    28

    Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.

    Published in:
    Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1223282
    By:
    • Grünwald, Viktor;
    • Powles, Thomas;
    • Masatoshi Eto;
    • Kopyltsov, Evgeny;
    • Sun Young Rha;
    • Porta, Camillo;
    • Motzer, Robert;
    • Hutson, Thomas E.;
    • José Méndez-Vidal, María;
    • Sung-Hoo Hong;
    • Winquist, Eric;
    • Goh, Jeffrey C.;
    • Maroto, Pablo;
    • Buchler, Tomas;
    • Toshio Takagi;
    • Burgents, Joseph E.;
    • Perini, Rodolfo;
    • Cixin He;
    • Okpara, Chinyere E.;
    • McKenzie, Jodi
    Publication type:
    Article
    29
    30
    31
    32
    33

    Systemic therapy in metastatic renal cell carcinoma.

    Published in:
    World Journal of Urology, 2017, v. 35, n. 2, p. 179, doi. 10.1007/s00345-016-1868-5
    By:
    • Bedke, Jens;
    • Gauler, Thomas;
    • Grünwald, Viktor;
    • Hegele, Axel;
    • Herrmann, Edwin;
    • Hinz, Stefan;
    • Janssen, Jan;
    • Schmitz, Stephan;
    • Schostak, Martin;
    • Tesch, Hans;
    • Zastrow, Stefan;
    • Miller, Kurt
    Publication type:
    Article
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45

    Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial.

    Published in:
    Oncology Research & Treatment, 2022, v. 45, n. 6, p. 319, doi. 10.1159/000521415
    By:
    • Goerling, Ute;
    • Gauler, Thomas;
    • Dietz, Andreas;
    • Grünwald, Viktor;
    • Knipping, Stephan;
    • Guntinas-Lichius, Orlando;
    • Frickhofen, Norbert;
    • Lindeman, Hans-Walter;
    • Fietkau, Rainer;
    • Haxel, Boris;
    • Große-Thie, Christina;
    • Maschmeyer, Georg;
    • Zipfel, Matthias;
    • Martus, Peter;
    • Knoedler, Maren;
    • Keilholz, Ulrich;
    • Klinghammer, Konrad
    Publication type:
    Article
    46
    47

    A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society

    Published in:
    Oncology Research & Treatment, 2020, v. 43, n. 7/8, p. 333, doi. 10.1159/000508450
    By:
    • Bergmann, Lothar;
    • Grünwald, Viktor;
    • Maute, Luise;
    • Grimm, Marc-Oliver;
    • Weikert, Steffen;
    • Schleicher, Jan;
    • Klotz, Theodor;
    • Greiner, Jochen;
    • Flörcken, Anne;
    • Hartmann, Arndt;
    • Gauler, Thomas
    Publication type:
    Article
    48
    49

    Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.

    Published in:
    Frontiers in Oncology, 2023, p. 01, doi. 10.3389/fonc.2023.1223282
    By:
    • Grünwald, Viktor;
    • Powles, Thomas;
    • Masatoshi Eto;
    • Kopyltsov, Evgeny;
    • Sun Young Rha;
    • Porta, Camillo;
    • Motzer, Robert;
    • Hutson, Thomas E.;
    • José Méndez-Vidal, María;
    • Sung-Hoo Hong;
    • Winquist, Eric;
    • Goh, Jeffrey C.;
    • Maroto, Pablo;
    • Buchler, Tomas;
    • Toshio Takagi;
    • Burgents, Joseph E.;
    • Perini, Rodolfo;
    • Cixin He;
    • Okpara, Chinyere E.;
    • McKenzie, Jodi
    Publication type:
    Article
    50